Methods of treating glioblastoma are provided comprising: administering a therapeutically effective amount of azeliragon, or a pharmaceutically acceptable salt thereof, and co-administering an effective amount of radiation therapy (RT), to a patient who has been diagnosed with glioblastoma. In another aspect, methods are provided for treating grade I, grade II, and grade III gliomas, the method comprising administering a therapeutically effective amount of azeliragon, or a pharmaceutically acceptable salt thereof, and co-administering an effective amount of radiation therapy (RT), to a patient who has been diagnosed with glioma.
Methods of treating glioblastoma are provided comprising: administering a therapeutically effective amount of azeliragon, or a pharmaceutically acceptable salt thereof, and co-administering an effective amount of radiation therapy (RT), to a patient who has been diagnosed with glioblastoma. In another aspect, methods are provided for treating grade I, grade II, and grade III gliomas, the method comprising administering a therapeutically effective amount of azeliragon, or a pharmaceutically acceptable salt thereof, and co-administering an effective amount of radiation therapy (RT), to a patient who has been diagnosed with glioma.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
Methods of treating glioblastoma, and grade I, grade II, and grade III gliomas are provided. The methods comprise administering a therapeutically effective amount of a RAGE inhibitor and coadministering an effective amount of radiation therapy (RT) to a patient who has been diagnosed with glioblastoma or glioma. In a further aspect, methods are provided for reducing MDSC concentrations in the microenvironment of solid tumors by administering a therapeutically effective amount of a RAGE inhibitor to a subject with, or having been diagnosed with, a solid tumor. In a further aspect, methods of treating cancer are provided, the method comprising administering a checkpoint inhibitor and co-administering a RAGE inhibitor in an amount and at a time effective to enhance activity of the checkpoint inhibitor. In preferred embodiments, the RAGE inhibitor is azeliragon or a pharmaceutically acceptable salt thereof.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
In a first aspect, methods of treating glioblastoma are provided. The method comprises administering a therapeutically effective amount of a RAGE inhibitor and coadministering an effective amount of radiation therapy (RT) to a patient who has been diagnosed with glioblastoma. In a further aspect, methods of treating cancer are provided, the method comprising administering a checkpoint inhibitor to a patient who has been diagnosed with cancer and co-administering a compound that inhibits the receptor for advanced glycation end products (RAGE) in an amount and at a time effective to enhance activity of the checkpoint inhibitor. In preferred embodiments, the RAGE inhibitor is azeliragon or a pharmaceutically acceptable salt thereof.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Pharmaceuticals; Pharmaceutical preparations for the treatment of cancer and other serious illnesses; Pharmaceutical preparations for inhibiting Receptor for Advanced Glycation End products (RAGE) interactions, for the treatment of cancer and other serious illnesses; Pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Pharmaceutical preparations for use in personalized medicine and targeted therapy. Pharmaceutical research and development; Development of new drugs for the prevention and treatment of cancer and other serious illnesses; Design and testing of new drugs and therapies; Medical and scientific research in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Medical and scientific research consulting in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Biological testing and research in the field of pharmaceuticals; Providing medical and scientific research information about the diagnosis and treatment of diseases; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing information in the fields of health and wellness (health), and pharmaceuticals via a website. Licensing of pharmaceuticals and drug discovery technologies.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Pharmaceuticals, namely, Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses; Pharmaceutical preparations for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for inhibiting Receptor for Advanced Glycation End products (RAGE) interactions, for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases; Pharmaceutical preparations for the treatment and prevention of diseases and disorders in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Pharmaceutical preparations for use in personalized medicine and targeted therapy in the field of Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Development of new drugs for the prevention and treatment of cancer and other serious illnesses; Design and testing of new drugs and therapies; Medical and scientific research in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Medical and scientific research consulting in the field of oncology, neurology, pulmonary, renal, cardiac, autoimmune, inflammatory, and infectious diseases; Biological testing and research in the field of pharmaceuticals; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses, namely, infectious diseases, viral diseases, and autoimmune diseases Providing medical and scientific research information about the diagnosis and treatment of diseases, namely, infectious diseases, viral diseases, and autoimmune diseases; Providing information in the fields of health, wellness, and pharmaceuticals via a website; all of the foregoing related to Receptor for Advanced Glycation End products (RAGE) inhibitors for the treatment of cancer and other serious illnesses Licensing of pharmaceuticals and drug discovery technologies
Methods of treating glioblastoma are provided comprising: administering a therapeutically effective amount of azeliragon, or a pharmaceutically acceptable salt thereof, and co-administering an effective amount of radiation therapy (RT), to a patient who has been diagnosed with glioblastoma. In another aspect, methods are provided for treating grade I, grade II, and grade III gliomas, the method comprising administering a therapeutically effective amount of azeliragon, or a pharmaceutically acceptable salt thereof, and co-administering an effective amount of radiation therapy (RT), to a patient who has been diagnosed with glioma.
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
Provided herein are methods and compositions related to using 2-O, 3-O desulfated heparin (ODSH, dociparstat sodium, [DSTAT]) for treating acute lung infections and related conditions or diseases. In certain embodiments the methods relate to treating coronavirus-mediated lung injuries.
A61K 31/41 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec plusieurs hétéro-atomes cycliques, l'un au moins étant l'azote, p. ex. tétrazole
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 31/4706 - 4-Aminoquinoléines8-Aminoquinoléines, p. ex. chloroquine, primaquine
A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
This application relates to methods and compositions for the administration of disulfiram (DSF) and heavy metals zinc and copper for the treatment and prevention of medical conditions, such as cancer. DSF and copper as well as DSF and zinc form active complexes that have been shown to be effective in the treatment of cancers. However, as described herein, DSF is incompatible with either copper or zinc for simultaneous oral administration. Included herein are improved methods and oral dosage forms comprising DSF and copper and DSF and zinc in fixed dose combinations that are configured to temporally stagger release of either DSF and copper or DSF and zinc after ingestion.
A61K 31/145 - Amines, p. ex. amantadine ayant des atomes de soufre, p. ex. thiurames (N-C(S)-S-C(S)-N ou N-C(S)-S-S-C(S)-N)Sulfinylamines (-N=SO)Sulfonylamines (-N=SO2)
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
This application relates to methods and compositions for the administration of disulfiram (DSF) and copper salt for the treatment and prevention of medical conditions, such as cancer. DSF and copper form active complexes that have been shown to be effective in the treatment of cancers. Included herein are improved methods for the adminstration of DSF and copper, wherein at least one of DSF or copper are adminstered by a parenteral route of adminstration.
A61K 31/145 - Amines, p. ex. amantadine ayant des atomes de soufre, p. ex. thiurames (N-C(S)-S-C(S)-N ou N-C(S)-S-S-C(S)-N)Sulfinylamines (-N=SO)Sulfonylamines (-N=SO2)
This application relates to methods and compositions for the administration of disulfiram (DSF) and heavy metals zinc and copper for the treatment and prevention of medical conditions, such as cancer. DSF and copper as well as DSF and zinc form active complexes that have been shown to be effective in the treatment of cancers. However, as described herein, DSF is incompatible with either copper or zinc for simultaneous oral administration. Included herein are improved methods and oral dosage forms comprising DSF and copper and DSF and zinc in fixed dose combinations that are configured to temporally stagger release of either DSF and copper or DSF and zinc after ingestion.
This application relates to methods and compositions for the administration of disulfiram (DSF) and heavy metals zinc and copper for the treatment and prevention of medical conditions, such as cancer. DSF and copper as well as DSF and zinc form active complexes that have been shown to be effective in the treatment of cancers. However, as described herein, DSF is incompatible with either copper or zinc for simultaneous oral administration. Included herein are improved methods and oral dosage forms comprising DSF and copper and DSF and zinc in fixed dose combinations that are configured to temporally stagger release of either DSF and copper or DSF and zinc after ingestion.
This application relates to methods and compositions for the administration of disulfiram (DSF) and heavy metals zinc and copper for the treatment and prevention of medical conditions, such as cancer. DSF and copper as well as DSF and zinc form active complexes that have been shown to be effective in the treatment of cancers. However, as described herein, DSF is incompatible with either copper or zinc for simultaneous oral administration. Included herein are improved methods and oral dosage forms comprising DSF and copper and DSF and zinc in fixed dose combinations that are configured to temporally stagger release of either DSF and copper or DSF and zinc after ingestion.
A61K 31/145 - Amines, p. ex. amantadine ayant des atomes de soufre, p. ex. thiurames (N-C(S)-S-C(S)-N ou N-C(S)-S-S-C(S)-N)Sulfinylamines (-N=SO)Sulfonylamines (-N=SO2)
A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
Disclosed herein are methods for the prevention and treatment of Graft Versus Host Disease (GVHD), particularly acute GVHD, including GVHD associated with hematopoeitc stem cell transplantation (HSCT), by administering HMGB1-interacting heparinoids to a subject at risk for, or suffering from, GVHD. In preferred embodiments, the methods comprise administering the HMGB1-interacting heparinoid in combination with corticosteroids.
Methods and compositions are presented for mobilizing hematopoietic stem cells (HSC) and for mobilizing T lymphocytes from the bone marrow and other compartments; use of the mobilized HSCs for HSC transplantation and mobilized T lymphocytes for T cell immunotherapy; for enhancing engraftment of transplanted HSCs and transferred T cells; and for enhancing recovery of hematopoietic system function following HSC transplantation or for enhancing engraftment and/or persistence of T cells following transfer for T cell immunotherapy.
Methods are presented for treating cancers and hematopoietic stem cell disorders, comprising administering to a subject with a cancer or hematopoietic stem cell disorder who is receiving a treatment regimen, a heparin derivative capable of inhibiting, reducing, abrogating or otherwise interfering with the binding of CXCL12 to CXCR4, wherein the cancer or hematopoietic stem cell disorder is one in which interaction of CXCL12 with CXCR4 privileges the cancer or disordered HSCs against therapeutic intervention. In preferred embodiments, the heparin derivative is a substantially 2-O, 3-O-desulfated heparin derivative.
Methods are presented for treating cancers and hematopoietic stem cell disorders, comprising administering to a subject with a cancer or hematopoietic stem cell disorder who is receiving a treatment regimen, a heparin derivative capable of inhibiting, reducing, abrogating or otherwise interfering with the binding of CXCL12 to CXCR4, wherein the cancer or hematopoietic stem cell disorder is one in which interaction of CXCL12 with CXCR4 privileges the cancer or disordered HSCs against therapeutic intervention. In preferred embodiments, the heparin derivative is a substantially 2-O, 3-O-desulfated heparin derivative.
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Multivalent cation compositions of partially desulfated heparins are presented. Multivalent cation compositions of the disclosure can be formulated at high concentrations. The compositions, processes for making the compositions, unit dosage forms, kits, and methods of treatment are also disclosed.
A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The invention relates to methods of treating and preventing radiation damage from whole-body exposure. According to the methods of the invention, subjects are treated therapeutically and/or prophylactically with low-anticoagulant heparinoids. The invention also relates to methods of extending the life of subjects exposed to whole-body radiation.
The present application provides methods of treating and preventing infections in the lung, such as Pseudomonas infections, comprising administering substantially non- anticoagulant 2-0, 2-0 desulfated heparin (ODSH) to subjects suffering from, or at risk for, chronic or acute pulmonary infections. ODSH can be administered alone or in combination with one or more other therapeutic agents, such as anti-microbial or antibiotic agents, mucolytic agents, DNases, bronchodilators, and anti-inflammatory agents. Also, provided herein are pharmaceutical compositions and unit dosage forms of ODSH, optionally in combination with other therapeutic agents, for use in the disclosed methods.
Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.
Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.
Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A method and medicament for treating and preventing platelet activation or thrombosis in the presence of heparin-and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater and an average molecular weight or 2.4 kD or greater. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin.
A method and medicament for treating and preventing platelet activation or thrombosis in the presence of heparin- and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater and an average molecular weight or 2.4 kD or greater. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-0 desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin.
